CY3 Stock Overview
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
DMK Pharmaceuticals Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.44 |
| 52 Week High | US$25.38 |
| 52 Week Low | US$3.12 |
| Beta | 1.21 |
| 1 Month Change | 0% |
| 3 Month Change | 6.03% |
| 1 Year Change | -84.99% |
| 3 Year Change | -93.46% |
| 5 Year Change | -98.35% |
| Change since IPO | 395.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| CY3 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.3% | -1.5% |
| 1Y | -85.0% | -30.8% | 0.9% |
Return vs Industry: CY3 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: CY3 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| CY3 volatility | |
|---|---|
| CY3 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CY3 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CY3's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 12 | Eboo Versi | www.dmkpharmaceuticals.com |
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.
DMK Pharmaceuticals Corporation Fundamentals Summary
| CY3 fundamental statistics | |
|---|---|
| Market cap | €6.40m |
| Earnings (TTM) | -€22.93m |
| Revenue (TTM) | €4.63m |
1.4x
P/S Ratio-0.3x
P/E RatioIs CY3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CY3 income statement (TTM) | |
|---|---|
| Revenue | US$5.05m |
| Cost of Revenue | US$6.51m |
| Gross Profit | -US$1.46m |
| Other Expenses | US$23.57m |
| Earnings | -US$25.02m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.30 |
| Gross Margin | -28.83% |
| Net Profit Margin | -495.08% |
| Debt/Equity Ratio | -1.4% |
How did CY3 perform over the long term?
See historical performance and comparison